Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…
Sponsor: NRG Oncology
NCT ID: NCT07166406
Sites in Missouri: - Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- Siteman Cancer Center at Christian Hospital — St Louis, Missouri
Phase 2, Phase 3 Recruiting Industry
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT06109272
Sites in Missouri: - Washington University-School of Medicine /ID# 255720 — St Louis, Missouri
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Missouri: - Saint Luke?s Hospital of Kansas City — Kansas City, Missouri
Phase 2 Recruiting NIH
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in Missouri: - Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- University of Kansas Cancer Center - Briarcliff — Kansas City, Missouri
- University of Kansas Cancer Center - North — Kansas City, Missouri
- University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Missouri: - David C. Pratt Cancer Center — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…
Sponsor: Tvardi Therapeutics, Incorporated
NCT ID: NCT05440708
Sites in Missouri: - Washington University in St. Louis — St Louis, Missouri
Phase 1, Phase 2 Recruiting Network
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…
Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1, Phase 2 Recruiting Industry
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GP…
Sponsor: AstraZeneca
NCT ID: NCT06795022
Sites in Missouri: - Research Site — St Louis, Missouri
Phase 1 Recruiting Industry
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events a…
Sponsor: AbbVie
NCT ID: NCT06858813
Sites in Missouri: - Washington University /ID# 275757 — St Louis, Missouri
Phase 1 Recruiting Industry
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101wil…
Sponsor: Angiex, Inc.
NCT ID: NCT06440005
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Phase 1 Recruiting Industry
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are des…
Sponsor: ViroMissile, Inc.
NCT ID: NCT06910657
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Missouri: - Massive Bio SYNERGY-AI site — Kansas City, Missouri
- Massive Bio SYNERGY-AI site — St Louis, Missouri
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Missouri: - Saint Luke's Cancer Institute, East — Kansas City, Missouri
- Saint Luke's Cancer Institute — Kansas City, Missouri
- Saint Luke's Cancer Institute, Kansas City North — Kansas City, Missouri
- Saint Luke's Cancer Institute, Liberty — Liberty, Missouri
- North Kansas City Hospital — North Kansas City, Missouri
NA Recruiting NIH
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Recruiting Industry
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multi…
Sponsor: AstraZeneca
NCT ID: NCT06252753
Sites in Missouri: - Research Site — Osage Beach, Missouri
Phase 4 Recruiting Industry
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x…
Sponsor: Guerbet
NCT ID: NCT04373564
Sites in Missouri: - Department of Radiology — St Louis, Missouri
Recruiting Industry
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-u…
Sponsor: Elephas
NCT ID: NCT07327489
Sites in Missouri: - Mercy Hospital - SPG — Springfield, Missouri
- Mercy Hospital - South — St Louis, Missouri
- Mercy Hospital -STL — St Louis, Missouri
Recruiting Academic/Other
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cel…
Sponsor: University of Missouri-Columbia
NCT ID: NCT02838836
Sites in Missouri: - Ellis Fischel Cancer Center, University of Missouri — Columbia, Missouri
Recruiting Academic/Other
Female patients with early onset (\<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk of prematu…
Sponsor: Washington University School of Medicine
NCT ID: NCT06904365
Sites in Missouri: - Washington University School of Medicine — St Louis, Missouri
Recruiting Academic/Other
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Also, early detection of lung cancer with low dose CT screening may c…
Sponsor: University of Missouri-Columbia
NCT ID: NCT03551951
Sites in Missouri: - Harry S Truman Veterans Memorial Hospital — Columbia, Missouri